Recombinant vectors expressing antigens of avian influenza virus and uses thereof
The present invention provides recombinant viral vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant viral vectors, polyvalent vaccines comprising the recombinant viral vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant viral vectors.
1. A composition or vaccine comprising one or more recombinant herpesvirus of turkeys (HVT) viral vectors,
wherein at least one HVT vector comprises one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian influenza virus;
wherein at least one of the one or more heterologous polynucleotides encodes an HA antigen; and
wherein the heterologous polynucleotide coding for and expressing the HA antigen comprising the amino acid sequence as set forth in SEQ ID NO: 2, 4, 20, 21, 22, 23, 24, 25, 26, 27, or 28 or wherein the heterologous polynucleotide encoding a polypeptide coding for the HA antigen comprising at least 75% sequence identity to the sequence as set forth in SEQ ID NO:1 or 3, or 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17.
2. The composition or vaccine of claim 1 , wherein the polynucleotide encoding the HA antigen is operably linked to a promoter selected from the group consisting of an immediate early cytomegalovirus (CMV) promoter, guinea pig CMV promoter, an SV40 promoter, Human Herpesvirus Type III glycoprotein B (HHV3gB) promoter, Pseudorabies Virus promoters, glycoprotein X promoter, Herpes Simplex Virus-1 alpha 4 promoter, a Marek's Disease Virus glycoprotein A (or gC) promoter, a Marek's Disease Virus glycoprotein B promoter, a Marek's Disease Virus glycoprotein E promoter, a Marek's Disease Virus glycoprotein I promoter, an Infectious Laryngotracheitis Virus glycoprotein B, an Infectious Laryngotracheitis Virus glycoprotein E promoter, an Infectious Laryngotracheitis Virus glycoprotein D promoter, an Infectious Laryngotracheitis Virus glycoprotein I promoter, vaccinia H6, and a combination thereof.
3. The composition or vaccine of claim 1 , wherein the polynucleotide encoding the HA antigen is inserted in the region selected from the group consisting of the IG1 locus (UL55), the IG2 locus, the IG3 locus, the UL43 locus, the US10 locus, and the SORF3/US2 locus on the HVT genome.
4. The composition or vaccine of claim 1 , wherein the HA antigen comprises a mutated HA cleavage region having the sequence as set forth in SEQ ID NO:15.
5. The composition or vaccine of claim 1 , wherein the composition or vaccine further comprises a second viral vector comprising a heterologous polynucleotide coding for and expressing at least one antigen of an avian influenza virus.
6. The composition or vaccine of claim 5 , wherein the second viral vector is selected from a herpesvirus of turkeys (HVT) or a fowlpox virus (FPV).
7. The composition or vaccine of claim 5 , wherein the second viral vector comprises a heterologous polynucleotide coding for and expressing an HA antigen having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO:2 or 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4, 20, 21, 22, 23, 24, 25, 26, 27, or 28.
8. The composition or vaccine of claim 5 , wherein the second viral vector comprises a heterologous polynucleotide encoding a polypeptide coding for the HA antigen having at least 75% sequence identity to the sequence as set forth in SEQ ID NO:1, 3, 8, 9, 10, 12, 13, 17 or 19.
9. The composition or vaccine of claim 1 , wherein the composition or vaccine further comprises a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant.
10. A recombinant herpesvirus of turkeys (HVT) viral vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian influenza virus; wherein at least one of the one or more heterologous polynucleotides encodes an HA antigen; and
wherein the heterologous polynucleotide coding for and expressing the HA antigen comprising the amino acid sequence as set forth in SEQ ID NO: 2, 4, 20, 21, 22, 23, 24, 25, 26, 27, or 28 or wherein the heterologous polynucleotide encoding a polypeptide coding for the HA antigen comprising at least 75% sequence identity to the sequence as set forth in SEQ ID NO:1 or 3, or 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17.
11. The recombinant viral vector of claim 10 , wherein the polynucleotide encoding the HA antigen is operably linked to a promoter selected from the group consisting of an immediate early cytomegalovirus (CMV) promoter, mouse CMV IE promoter, guinea pig CMV promoter, an SV40 promoter, Human Herpesvirus Type III glycoprotein B (HHV3gB) promoter, Pseudorabies Virus promoters, glycoprotein X promoter, Herpes Simplex Virus-1 alpha 4 promoter, a Marek's Disease Virus glycoprotein A (or gC) promoter, a Marek's Disease Virus glycoprotein B promoter, a Marek's Disease Virus glycoprotein E promoter, a Marek's Disease Virus glycoprotein I promoter, an Infectious Laryngotracheitis Virus glycoprotein B, an Infectious Laryngotracheitis Virus glycoprotein E promoter, an Infectious Laryngotracheitis Virus glycoprotein D promoter, an Infectious Laryngotracheitis Virus glycoprotein I promoter, vaccinia H6, and a combination thereof.
12. The recombinant viral vector of claim 10 , wherein the polynucleotide encoding the HA antigen is inserted in the region selected from the group consisting of the IG1 locus (UL55), the IG2 locus, the IG3 locus, the UL43 locus, the US10 locus, and the SORF3/US2 locus on the HVT genome.
13. The recombinant viral vector of claim 10 , wherein the HA antigen comprises a mutated HA cleavage region having the sequence as set forth in SEQ ID NO:15.
14. A method of vaccinating an animal or for inducing an immunogenic or protective response in an animal against avian influenza pathogens, comprising at least one administration of the composition of claim 1 or vector of claim 10 .
15. The method of claim 14 , wherein the administration comprises a prime-boost administration regimen.
16. The method of claim 15 , wherein the prime-boost administration comprises a prime-administration of a composition or vaccine or a polyvalent composition or vaccine comprising one or more viral vectors selected from the group consisting of HVT and FPV, wherein if there is only one viral vector, the viral vector is HVT, and a boost-administration of a composition or vaccine or a polyvalent composition or vaccine comprising one or more viral vectors selected from the group consisting of HVT and FPV which are the same or different from the viral vectors used in the prime-administration.
17. The method of claim 14 , wherein the animal is avian.
18. A recombinant viral vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian influenza virus, wherein:
the recombinant viral vector is a fowlpox virus (FPV); and
the recombinant viral vector comprises a heterologous polypeptide coding for and expressing an HA antigen
wherein the heterologous polynucleotide coding for and expressing the HA antigen comprising the amino acid sequence as set forth in SEQ ID NO: 2, 4, 20, 21, 22, 23, 24, 25, 26, 27, or 28 or wherein the heterologous polynucleotide encoding a polypeptide coding for the HA antigen comprising at least 75% sequence identity to the sequence as set forth in SEQ ID NO:1 or 3, or 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17.
19. The recombinant viral vector of claim 18 , wherein the polynucleotide encoding the HA antigen is operably linked to a promoter selected from the group consisting of an immediate early cytomegalovirus (CMV) promoter, mouse CMV IE promoter, guinea pig CMV promoter, an SV40 promoter, Human Herpesvirus Type III glycoprotein B (HHV3gB) promoter, Pseudorabies Virus promoters, glycoprotein X promoter, Herpes Simplex Virus-1 alpha 4 promoter, a Marek's Disease Virus glycoprotein A (or gC) promoter, a Marek's Disease Virus glycoprotein B promoter, a Marek's Disease Virus glycoprotein E promoter, a Marek's Disease Virus glycoprotein I promoter, an Infectious Laryngotracheitis Virus glycoprotein B, an Infectious Laryngotracheitis Virus glycoprotein E promoter, an Infectious Laryngotracheitis Virus glycoprotein D promoter, an Infectious Laryngotracheitis Virus glycoprotein I promoter, vaccinia H6, and a combination thereof.
20. The recombinant viral vector of claim 18 , wherein the polynucleotide encoding the HA antigen is inserted in the region selected from the group consisting of the F7 locus and the F8 locus on the FPV genome.
21. The recombinant viral vector of claim 18 , wherein the HA antigen comprises a mutated HA cleavage region having the sequence as set forth in SEQ ID NO:15.
22. A recombinant viral vector comprising a heterologous polynucleotide having at least 75% sequence identity to the sequence as set forth in SEQ ID NO: 8, 9, 10 or 19, or 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 12 or 13.